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Abstract The Brain Donation Program at Sun
Health Research Institute has been in continual
operation since 1987, with over 1000 brains
banked. The population studied primarily resides
in the retirement communities of northwest metro-
politan Phoenix, Arizona. The Institute is afﬁliated
with Sun Health, a nonproﬁt community-owned and
operated health care provider. Subjects are enrolled
prospectively to allow standardized clinical assess-
ments during life. Funding comes primarily from
competitive grants. The Program has made short
postmortem brain retrieval a priority, with a 2.75-h
median postmortem interval for the entire collec-
tion. This maximizes the utility of the resource for
molecular studies; frozen tissue from approximately
82% of all cases is suitable for RNA studies.
Studies performed in-house have shown that, even
with very short postmortem intervals, increasing
delays in brain retrieval adversely affect RNA
integrity and that cerebrospinal ﬂuid pH increases
with postmortem interval but does not predict tissue
viability.
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Introduction
Purpose and mission
The clinical syndromes generated by Alzheimer’s
disease (AD) and other neurodegenerative disorders
are not pathognomonic diagnostic phenomena.
Neuropathological examination of the postmortem
brain is the only means by which a deﬁnite diagnosis
can be attained. The purpose of brain banks is to
provide neuropathologically characterized brain tis-
sue to basic scientists, enabling them to discover the
underlying molecular mechanisms speciﬁc to each
disease, thereby allowing the design of appropriate
therapeutic interventions. A detailed understanding of
the genetic and molecular processes of disease
pathogenesis, obtained by comparative study of
diseased and non-diseased brain tissue, remains the
major approach to ﬁnding such interventions. It is
noteworthy that for both Alzheimer’s and Parkinson’s
diseases, the existing approved pharmacotherapies
are all based on neurotransmitter deﬁciencies identi-
ﬁed from study of postmortem brains more than
30 years ago. The subsequent divergence of basic
scientiﬁc efforts into in vitro work has not generated
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studies of human brain, using new and powerful
technologies, is needed to generate a new wave of
fundamental discoveries.
The study population and research site
The primary population under study consists of the
retirement communities of northwest greater Phoe-
nix, especially Sun City, Sun City West and Sun City
Grand. A proﬁle of these communities has been
constructed using data from the US Census Bureau
(2000) and from the ﬁles of the Sun Cities Area
Historical Society. All of the communities have as
residency requirements a minimum age of 55 years.
The populations of Sun City, Sun City West and Sun
City Grand, respectively, are 38,306, 26,344 and
9,270 (total of 73,920 as of 2000). Sun City, ﬁrst
established in 1960, was one of the ﬁrst planned
retirement communities in the United States. Sun
City West and Sun City Grand followed, in 1978 and
1996, respectively. Due to a lack of new land
availability, the populations of all three communities
have stopped increasing. The population of Sun City
has been maintained at about 40,000 for 3 decades,
suggesting that a continued inﬂux of new retirees will
maintain the populations of all of the communities.
Future new developments are already planned, with
Sun City Festival Ranch now in its early stages. This
latest community is expected to add another 12,000
residents by 2010. Additionally, surrounding areas
contain a mix of retirees and young families.
Although migration of retirees to the region
occurred initially in three major waves, coinciding
with the establishment and marketing of housing
developments in Sun City, Sun City West and Sun
City Grand, the residents are all very similar, being
composed overwhelmingly of elderly, well-educated,
Caucasian, middle and upper income individuals
originating most commonly from Midwestern US
states. Initially there must have been some age
differences between the communities due to the
differences in their construction time, but continued
replacement of initial residents with later migrants
has almost erased the evidence of this, as the median
ages of the residents are 75, 78 and 75, for Sun City,
Sun City West and Sun City Grand, respectively. The
average residency time in Sun City is 12.6 years. As
there is very little outmigration, the turnover is
mostly due to deaths. Of the original Sun City
population, 90% were replaced by a second genera-
tion of retirees by 1990.
Sun Health Research Institute
Sun Health Research Institute (SHRI) is an afﬁliate of
Sun Health Corporation, a non-proﬁt, community
owned and operated health care provider. What is
now known as Sun Health was ﬁrst conceived in 1965
and was intended to serve the needs of Sun City,
Arizona, one of the ﬁrst planned retirement commu-
nities. Sun Health now serves not only the original
Sun City but also the adjacent retirement communi-
ties of Sun City West and Sun City Grand as well as
northwest greater Phoenix in general, all of which
have experienced rapid growth of both retirement and
non-retirement populations. Services provided by Sun
Health include medical insurance, two acute care
hospitals, extended and hospice care, outpatient
clinics and Alzheimer care residences. Sun Health
has recently announced that it will merge with
Banner Health, a larger not-for-proﬁt health care
provider with multiple facilities throughout greater
Phoenix as well as California, Utah and Colorado.
Sun Health Research Institute was established in
1986 with funds from Sun Health operations revenue
and charitable contributions to the Sun Health
Foundation. Initially known as the Institute for
Biogerontology Research, the Institute has grown
into one of the world’s largest privately-funded
research centers for age-related disorders. The focus
of the Institute’s scientiﬁc work has been, since its
inception, Alzheimer’s disease, with substantial Par-
kinson’s disease and arthritis research beginning in
1996. More recently there have been extensions into
ﬁbromyalgia, orthopedic and prostate cancer
research. Since 1998, the Institute has been part of
the Arizona Alzheimer’s Consortium (AAC), a state-
funded alliance that includes Sun Health Research
Institute, the University of Arizona, Tucson Veteran’s
Administration Medical Center, Barrow Neurological
Institute, the Arizona Mayo Clinic, Arizona State
University and the Banner Health/Good Samaritan
Hospital system. The same consortium was awarded
a National Institutes on Aging Alzheimer’s Disease
Core Center (ADCC) in 2001 and a state-funded
Arizona Parkinson’s Disease Center in 2002. Both of
these are headquartered at SHRI.
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Institute
The Brain Donation Program has been in existence
since 1987 and has enrolled more than 2500 donors
over that time, which constitutes about 2% of the
current combined populations of the surrounding
retirement communities. Of these, 1042 donors have
expired and their brains have been collected and
stored, while there are 1061 living donors. Donors
have all volunteered speciﬁcally for the program and
are highly motivated, with an annual drop-out rate of
only 1.8%. Recruitment relied initially on hospital
staff, who obtained consents from family members of
individuals who died while admitted. Recruitment
gradually became almost entirely done on a prospec-
tive basis, primarily by word-of-mouth, through
interactions of the population with physicians and
nursing staff belonging to the Sun Health provider
network, and through public speaking events and
tours of the Institute given by Institute staff to
community groups and the general public. Institute
staff give approximately 60 such public interactive
events each year. Relatively frequent media releases
also contribute to recruitment. Eligibility criteria for
the Program are simple in that the subjects must be
free of hazardous infectious diseases and must
consent to annual clinical assessments at SHRI.
Additionally, at least two years of the applicant’s
private medical records must be received and
reviewed by Brain Donation Program staff prior to
acceptance. The medical records review is directed
mainly at excluding hazardous infectious disease
conditions. All enrolled subjects or legal representa-
tives sign an Institutional Review Board-approved
informed consent form allowing both clinical assess-
ments during life and several options for brain and/or
bodily organ donation after death. A separate section
requests the subject to allow or disallow DNA
isolation and storage as well as genetic testing.
Donors are allowed to withdraw from the program at
any time. When a donor loses his/her mental
capability, ordinarily a family member will be
appointed as the donor’s legal representative. That
legal representative would then have the power to
withdraw the donor from the program. The informed
consent has a section that fully discloses the possible
commercial use of our tissue, stating that SHRI,
personnel from SHRI, personnel from other
institutions, or other organizations that utilize our
tissue may obtain monetary beneﬁt from the use of
the tissue.
Between 1987 and 1995 brain donors did not
receive formal neuropsychological testing. Their
mental status was determined by requisitioning
medical records from their primary care physicians,
neurologists, psychologists and psychiatrists, and
through telephone interviews with family members
and caregivers, both at the time of enrollment and in
the immediate postmortem period. In 1996 a clinical
psychologist was hired and from then onwards, a
standardized neuropsychological screening assess-
ment has been administered to most of the subjects
enrolled in the Brain Donation Program. Also since
1996, most donors have received a standardized
neurological evaluation tailored to detect overt and
incipient movement disorders. In 2000, the clinical
operations of the Program were greatly expanded,
with the hiring of a neurologist, another neuropsy-
chologist and associated support staff, allowing the
administration of a full neuropsychological test
battery. If a previously undetected medical abnor-
mality is discovered in the course of the annual
clinical assessment, the donor is informed and
advised to visit their physician for further investiga-
tion and/or treatment. The SHRI physician will also
ask the donor’s permission to inform their private
physician of this ﬁnding.
Consideration of sampling issues
Subjects from the Sun Cities are not an accurate
representative sample of the entire US elderly
population, in that they lack racial diversity and are
more highly educated, have higher incomes and live
longer than the average US citizen. Although the
study population lacks the diversity of the general US
population, there are advantages of using a more
homogeneous group. The use of homogeneous pop-
ulations with minimal genetic and environmental
variability decreases the subject number required to
attain adequate statistical power. This has been
recognized by many researchers and has been used,
for example, by groups utilizing isolated populations
to study inheritance (Adachi et al. 1992; Johanneson
et al. 1999; Lio et al. 2003; Mathews et al. 2004;
Peschken and Esdaile 1999). However, studying a
homogeneous group allows the possibility of missing
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be enriched in some ethnic groups but not in others.
The effect of selection bias on the study population
must be considered, as autopsy studies do not
represent random sampling. A recent study has
shown that subjects selected for autopsy do not differ
appreciably from those that are not autopsied (Lim
et al. 1999) but this may differ with locale. The issue
of ‘‘volunteer bias’’ has been raised, as some studies
have suggested that volunteers generally come from a
higher socioeconomic background than non-volun-
teers (Gustavsson et al. 1997; Mandel et al. 2000;
Sofuoglu et al. 2000). Volunteer bias may apply
differentially to normal and diseased subjects, as
normal subjects are almost always true volunteers
while diseased subjects are often enrolled by family
members after they have lost independent decision-
making capacity. Very elderly normal control sub-
jects might even be regarded as ‘‘supernormals’’
possessing a general genetic resistance to disease. We
have considered this possibility for our study popu-
lation. Queries of our database have shown, however,
that our Alzheimer’s disease and non-demented
control subjects have generally similar prevalences
of major disease conditions (Table 1). Control sub-
jects have a substantially higher prevalence of cancer
than AD subjects. Also, as the subjects had essen-
tially the same age at death, the possibility of a
‘‘survivor bias’’ between the two groups is ruled out.
The greater prevalence of a medical history of
coronary atherosclerotic disease and stroke in AD
subjects supports many previous similar reports.
Brain Donation Program Database
Prior to 1998, records were kept on paper in binders.
With the initiation of the computerized database, the
essential aspects of these records, including demo-
graphic, medical history and neuropathological
ﬁndings, were abstracted and entered into the com-
puterized database. Since 1998, the Institute has
developed a sophisticated database and database
management protocols, largely engineered by a
contracted professional industrial database consul-
tant. The clinical and neuropathology components of
the Brain Donation Program Database were designed
together and are completely integrated. The Database
is a customized elaboration of Microsoft Access and
My Sequel off-the-shelf programs. The current com-
bined clinical and neuropathology components take
up 218 megabytes. The Database is composed of 51
matrices with 1905 ﬁelds (separate data categories)
which collectively contain data pertaining to basic
demographic information, medical history, results of
standardized clinical assessments and, for autopsied
subjects, neuropathologic data, tissue inventory and
records of tissue requests and shipments. The Data-
base contains 53 forms to facilitate data entry and 75
different standing data reports that can be generated
with a single keystroke. The Database is also used to
ensure that scheduling of clinical assessments is done
at appropriate intervals. The current neuropathology
subsection of the Database has 330 ﬁelds, of which
the National Alzheimer’s Coordinating Center
(NACC) Neuropathology Data Set is a subset.
Numerous additional ﬁelds beyond the latter include
in-house grading methods for plaques, tangles, Lewy
bodies and white matter rarefaction, as well as ﬁxed
tissue quality, RNA quality and current inventory of
160 ﬁelds for ﬁxed tissue, frozen tissue, CSF and
blood serum. The Neuropathology Database tracks
tissue requests and requestors.
The Database is backed up automatically every
day on two servers administered by Sun Health
Information Services, located at two sites about 5
miles apart. Storage of data in both locations ensures
that structural damage to one server (e.g. ﬁre) does
not result in irretrievable loss. Both servers store
daily copies of databases for the preceding 30 days;
Table 1 Comparison of AD and control subjects—age at
death and disease class prevalence
Classiﬁcation Alzheimer’s
disease
Non-demented
controls
Age at death 80.5 79.9
Coronary artery
disease, %
16 7
Stroke, % 7 3
Diabetes, % 9 7
Cancer, % 10 16
Asthma/COPD, % 9 7
Macular degeneration,
%
34
Cataracts, % 7 9
Osteoporosis, % 9 13
Hearing impairment, % 2 4
Hypothyroidism, % 12 17
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contracted for this purpose. Storage of older database
copies allows the recovery of an intact database in the
event of inadvertent errors in database operation,
hardware malfunction or software malfunction.
The SHRI Brain Donation Program Database has
been managed by informal groups that have included
the database designer, a statistician, the directors of
the clinical and neuropathology cores and the major
database operators. This arrangement has worked
very well as it includes the individuals who use the
database day-to-day, the physician–scientists that will
be collecting the data, and the database designer, who
can make changes to the database as necessary.
Conﬁdentiality of human subject data in the
Database is assured by multiple safeguards which
restrict access to personal identifying information
such as name, date of birth, date of death, address and
gender. Data entry is restricted to as few personnel as
possible. Access to the Database requires a unique
user name and password, and all transactions are
tracked and stored in an electronic log, allowing
identiﬁcation of inappropriate or incorrect usage by
any individual. Access to the Sun Health local area
network is protected by a ﬁrewall maintained by Sun
Health Information Services. Paper copies of subject
records are kept in locked ﬁling cabinets in the ofﬁces
of the major database operators. Sun Health Research
Institute has been issued a Certiﬁcate of Conﬁdenti-
ality by the US Secretary of Health and Human
Services, protecting human subjects’ data from court
subpoena.
Institute researchers are able to obtain an up-to-
date copy of the Database, minus personal identifying
information, at any time upon request. A standing
query is used to produce this, following which the
database copy is copied onto a portable memory
storage device which the researcher may then load
onto his/her own computer. Standard Microsoft
Access software, which is provided by Sun Health,
will run the database copy. For database queries
involving detailed knowledge of clinical or neuropa-
thologic criteria, the directors of neurology and
neuropathology assist the researchers with query
design.
All data are subjected automatically to an error
checking program that identiﬁes out of range, illog-
ical and missing data. In addition, a random sample
of subject records is compared directly with data
forms (paper copy) on a periodic basis to reduce data
entry mistakes.
Flow of subjects through the Brain and Body
Donation Program Clinical Core
The ﬂow of subjects through the Brain and Body
Donation Program Clinical Core over the 5 year
period between January 1, 2001 and December 31,
2006 is illustrated in Fig. 1. Note that this summary
applies exclusively to subjects seen at Sun Health
Research Institute and does not include subjects that
were seen clinically at other institutions participating
in our Arizona ADCC. On January 1, 2001 there were
255 living subjects enrolled in the Brain and Body
Donation Program. This initial input of subjects was
supplemented by 1078 new subjects recruited by the
Clinical Core over the following 5-years, giving a
total of 1332 subjects that ﬂowed through the Clinical
Core over this time period. There are two major
pathways that subjects followed over this 5-year
period, depending on whether or not they received a
standardized clinical assessment by Core personnel.
Although it is a requirement of the Program that
donors consent to annual standardized clinical assess-
ments at SHRI, and considerable efforts are expended
to have every subject assessed, inevitably some
(currently less than 10%) of our living subjects die
without a standardized assessment. There are various
reasons why not all subjects are assessed. Some
subjects are in a terminal phase of illness when they
register with the Program and die or become
incapacitated before an assessment can be done,
while others have difﬁculty scheduling an appoint-
ment for various reasons. A common impediment is a
lack of someone to bring them in if they are not able
to drive themselves. Some donors had enrolled in the
Program prior to when clinical assessments became
mandatory and are therefore allowed to remain as
brain donors only. For normal control cases that die
without a standardized clinical assessment at SHRI,
or whose last SHRI assessment was more than a year
prior to death, an effort is made to obtain postmortem
functional assessments by using telephone interviews
with informants. The Dementia Questionnaire (DQ)
has been used for this purpose, with 42 postmortem
DQ assessments obtained between July 1, 2000 and
August 1, 2007. The DQ has been validated in
subjects who had both a premortem clinical diagnosis
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a high speciﬁcity and sensitivity for the presence of
dementia (93% and 89%, respectively), and also has a
high interrater agreement (98%).
Neuropathology Core and Brain Banking
Operations
Dedication to short postmortem interval
Since the inception of the Brain Donation Program,
the overriding organizing principle has been that the
brain must be removed and processed as rapidly as
possible. The median postmortem interval (PMI),
deﬁned as the time elapsing between death and brain
removal, for all 1042 of our necropsied subjects, is
2.75 h (mean 3.92; standard deviation 5.11; range
1–70). There is a moderately extensive literature on
the relationship between PMI and brain tissue quality,
which will not be exhaustively summarized here, but
it is apparent that deterioration of molecular entities
after death varies widely depending on what is being
measured. Highly volatile energy storage molecules
such as ATP disappear within minutes (Ravid et al.
1992), catecholamines drop precipitously within the
ﬁrst few hours (Hynd et al. 2003; Palmer et al. 1988;
Spokes and Koch 1978; Spokes 1979) while high-
molecular-weight DNA may be stable for up to
20 days after death (Ludes et al. 1993). Some
enzyme activities actually increase after death, for
example, creatine kinase activity is increased more
than ten-fold at 2 h postmortem (Karkela 1993). Most
protein and RNA species are surprisingly stable up to
40–50 h postmortem (Cummings et al. 2001; Ferrer
et al. 2007; Hynd et al. 2003; Johnson et al. 1986;
McGeer and McGeer 1976; Preece and Cairns 2003;
Stan et al. 2006; Tomita et al. 2004; Vonsattel et al.
1995). As the majority of biomedical research is done
on proteins and RNA, this might suggest that
postmortem intervals up to 36 or even 48 h might
be sufﬁcient for authoritative studies, but there is also
evidence that appreciable numbers of speciﬁc pro-
teins and RNA transcripts show large PMI-dependent
reductions, even within the ﬁrst 4–8 h (Catts et al.
2005; Ferrer et al. 2007; Hynd et al. 2003; Pardue
et al. 1994). Variability in postmortem preservation
of different mRNA transcripts may be due to
differing tertiary structures or normal physiological
half-lives, which range from minutes to days. For
example, c-fos mRNA has a half-life of 15 min while
that for globin mRNA is 50 h (Hynd et al. 2003).
Some intensely-studied proteins are markedly
degraded within the ﬁrst 4–8 h of death, including
a-synuclein and sarkosyl-insoluble tau (Ferrer et al.
2007a). The postmortem integrity of post-transla-
tional protein modiﬁcations is largely unknown,
Total
Subject
Input
N = 1332 
100%
Subjects  With 
1 or More 
Clinical Core 
Assessments 
N = 915 
69%
Subjects
Without a 
Clinical Core 
Assessment 
N = 417 
31%
Autopsied,
Assessed by 
Clinical Core 
N = 228 
17%
Autopsied,
Not Clinically  
Assessed
N = 87 
6.5%
Died, not 
Autopsied
N = 58 
4.3%
Still Living 
and Enrolled 
N = 808 
61%
Dropped
N = 151 
11.3%
Neuropathology
Core Cases 
N = 315 
23.6%
Postmortem
Functional
Assessment 
N = 22 
1.6%
Fig. 1 Subject ﬂow
through the Brain Donation
Program 01/01/01–12/31/
06. Percentages are
calculated with respect to
total subject input
234 Cell Tissue Banking (2008) 9:229–245
123although it has been reported that tau protein is
dephosphorylated within 30 min after death (Gartner
et al. 1998).
We have evaluated RNA integrity in 157 cases
(mean PMI 3.1 h) from our brain bank using
qualitative RNA agarose gel electrophoresis. The
presence of two clearly distinct and dominant bands,
corresponding to the ribosomal 28S and 18S RNA
species, as recorded by a single observer blinded to
all case data, was used to deﬁne acceptable RNA.
Loss or smearing of these bands was used to indicate
degradation levels making the sample unsuitable for
study. Using these criteria, 133/157, or 82% of our
samples were suitable for RNA studies and were used
successfully. Comparison of PMI’s from cases giving
suitable and unsuitable RNA showed a signiﬁcantly
shorter mean PMI in the suitable samples (2.75 vs
3.5 h, two-tailed unpaired t-test; P = 0.04). These
results suggest that even small differences in PMI
within a rapid autopsy program can have a signiﬁcant
effect on RNA integrity. As a further comparison,
programs with average PMI’s of 16 h or more have
reported one-third to one-half of cases have RNA
suitable for molecular research methods (Vanderburg
et al. 2005; Vonsattel et al. 1995) whereas we have
found 82% of cases suitable. These results and the
brief literature review presented here indicate that a
short PMI clearly allows optimal use of the resource
but that all postmortem studies must evaluate the
inﬂuence of PMI as it is dependent on the speciﬁc
molecular forms under investigation.
On-call brain removal teams
The maintenance of a rapid autopsy program requires
sufﬁcient stafﬁng to prevent ‘‘burnout’’. Most rapid
autopsy programs fail because of understafﬁng. Our
experience has led to the conclusion that it is
advisable to limit on-call periods for any one
individual to no more than 4 months per year. The
minimum number of persons required for each callout
is two, for both safety and efﬁciency reasons. We
have three rotating on-call teams, each consisting of a
team leader and one assistant. The team leaders, who
are employees of the Neuropathology Core of the
Brain Donation Program (they also serve as histology
technicians during regular hours), receive training
from the neuropathologist and coordinator and are on
call every third month, while the assistants, derived
from volunteers amongst the entire SHRI scientiﬁc,
technical and administrative staff, generally serve for
1–3 months per year. Team leaders and assistants are
paid a bonus for each callout. As another strategy to
avoid on-call team burnout, we continually optimize
procedures to minimize brain processing time.
Generally we complete all procedures in less than
2.5 h and the total time a team member spends on a
call, including transportation to and from their home,
is between 3 and 4 h. To expedite brain processing,
we always have made preparations for 2–3 autopsies
into the future. Having a permanent dedicated
autopsy suite enables all tools and equipment to be
laid out ready for use; we also prelabel all containers
and bags.
Time-of-death telephone protocol and cadaver
transport
When subjects registered into the Brain Donation
Program die, their caregivers, usually at a nursing
home, follow the instructions given to them by the
family, which were mailed to the family at the time of
acceptance into the Program. The instructions are
simple and require only that the caregiver telephone
the Institute as soon as possible after death. If the call
is after-hours, it is transferred to the operator at one of
Sun Health’s acute care hospitals. The on-call team
leader is then paged by the hospital operator and calls
in to receive the contact information. The team leader
then calls the contact, usually the caregiver at the
nursing home, and conducts a short interview to
ascertain the subject’s identity, conﬁrm that they are
registered in the Program, and record the subject’s
current charted medical history conditions. The team
leader also asks whether the subject has speciﬁc
hazardous infectious diseases (see later section on
safety for details). Subjects who die within the greater
Phoenix metropolitan area are transported to the
SHRI morgue by a contracted commercial cadaver
transport company. Longer distances have propor-
tionately greater charges and the PMI becomes
progressively longer. For these reasons, we only
accept cases that die within an approximate 50 mile
radius and the informed consent details this so that
the family is aware. These transportation companies
normally serve funeral homes on a 24 h basis and
therefore are ideally suited for our rapid autopsy
program. All charges are borne by the Program;
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aspect relating to their donation.
Blood and CSF draw, brain removal, gross dissection
and initial tissue processing
Prior to removing the brain, cerebrospinal ﬂuid
(CSF) is drawn from the lateral ventricles and heart
blood is drawn from the left ventricle by transtho-
racic puncture, using 30 ml disposable syringes
ﬁtted with 8 cm long, 18 guage needles. The CSF
is ejected into 15 ml disposable Falcon tubes for
centrifugation while the blood is converted to serum
by introduction into standard serum separator vac-
uum tubes (7 ml) prior to centrifugation. Although a
small fraction of blood is also taken into EDTA
vacuum tubes (4 ml each) for preparation of plasma,
this is not directly comparable to plasma from living
subjects as extensive postmortem coagulation would
have removed many clotting factors and other
proteins. About 20–30 ml of CSF, 5–10 ml of serum
and 4 ml of plasma are generally obtained. A
2–3 ml sample of blood serum is sent to a commer-
cial clinical pathology laboratory for syphilis, HIV
and hepatitis A, B and C serology. Remaining blood
serum as well as CSF is centrifuged and superna-
tants from both blood serum and CSF are aliquotted
into 1 ml microcentrifuge tubes and stored frozen
at -80C. Postmortem CSF has been said to be
unsuitable for research purposes due to postmortem
changes or due to its ventricular origin, but these
opinions appear to be purely anecdotal as we have
conducted an extensive literature search and found
no published evidence supporting these claims. We
have conducted extensive studies on postmortem
CSF (Castano et al. 2006) using Western blot,
ELISA and proteomic methodology and have
obtained results similar to those published by many
other groups, who have all used CSF from living
subjects. In our opinion, the beneﬁts obtained by
having precise neuropathological diagnoses for sub-
jects greatly outweighs the disadvantages conferred
by the presence of any minor postmortem changes.
We are presently conducting a detailed proteomic
comparison of CSF from living and deceased
subjects. Similar considerations apply to the usage
of postmortem blood fractions, which we have also
investigated extensively (Kuo et al. 1998, 1999,
2000a; Rogers et al. 2006).
Also prior to brain removal, and prior to CSF
draw, samples are taken of temporalis muscle and
scalp. Many neurological diseases can be diagnosed
or studied in muscle or skin and therefore we ﬁx and/
or freeze these samples along with the brain tissue.
We have published results for Ab concentrations in
these temporalis muscle samples (Kuo et al. 2000b)
and have done unpublished work on scalp samples
from AD and control subjects (ﬁnding no immuno-
histochemically-detectable Ab).
Brain removal is accomplished in the standard
fashion with an oscillating electric saw. To minimize
bacterial contamination of brain tissue, the scalp is
washed with an antibacterial solution. After the skull
cap is removed, the brain team leader changes to new
sterile gloves before moving the brain to the cutting
board, which has been prepared by wiping down with
70% ethanol. These precautions are in the interests of
our postmortem cell culture teams, which regularly
culture glial and vascular cells from the postmortem
brain tissue (Lue et al. 1996; Lue and Walker 2002;
Rogers et al. 2002; Walker and Lue 2005). The brain
is removed with as much cervical spinal cord as
possible. Following brain removal, the pituitary gland
is dissected from the sella turcica. Gross neuropatho-
logic examinations on brain external surfaces,
coronal cerebral slices and parasagittal cerebellar
slices are performed by the neuropathologist during
working hours. After-hours brains are photographed
at the time of removal, whole and after slicing with a
digital camera (Nikon D50) and dedicated software
that transmits the images directly to a computer hard-
drive (Nikon Capture 4). By reviewing the digital
images, the neuropathologist is then able to perform a
gross description on brains removed and processed
after-hours. The images may also be used for
morphometric analysis without the usual complica-
tion of correcting for volume changes due to ﬁxation.
The details of the brain dissection are as follows.
The olfactory bulbs and tracts as well as the pineal
gland are removed and the cerebellum and brainstem
are severed from the cerebrum by a transverse cut
across the rostral pons. The leptomeninges are
stripped from both cerebrum and cerebellum/brain-
stem for storage as research material (Roher et al.
2003). The cerebellum is separated from the brain-
stem by severing the cerebellar peduncles. Each
hemicerebellum is sliced into 4–5 segments in the
parasagittal plane. The brainstem is sliced into left
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approximately 0.8–1 cm segments in the coronal
plane. The left side slices are used for immersion
ﬁxation in freshly-prepared phosphate-buffered 4%
paraformaldehyde while the right side slices are
rapidly frozen between sheets of dry ice (20 9
20 9 3 cm).
This method of brain processing differs from the
conventional neuropathological examination, in
which the whole or half of the brain is immersed in
formaldehyde for 7–14 days before slicing. Although
it has been argued that fresh-slicing detracts from the
neuropathologic gross exam, we feel that it is
essential to slice the brain fresh, both to enable rapid
freezing and optimum ﬁxation. Freezing an intact
hemisphere slowly on dry ice or by placing it in an
ultralow-temperature freezer results in severe ice-
crystal artifact (Vonsattel et al. 1995), rendering the
tissue unsuitable for cryostat-section histological
examination, which has become increasingly impor-
tant as a method for molecular studies, especially
those utilizing confocal laser-capture microscopic
analysis. Also, the long-entrenched idea that rapid
freezing in liquid nitrogen or similar ﬂuids is
essential for molecular biological studies is simplistic
and incorrect. In fact, rapid freezing may cause
membrane damage while slow freezing in iso-
osmotic cyroprotectant is optimal for synaptosomal
preparations (Hynd et al. 2003). Our experience has
shown that freezing rapidly between sheets of dry ice
gives morphologically intact tissue suitable for a
wide range of molecular biological procedures,
including Western blot, ELISA, Northern blot, in-
situ hybridization, gene microarray, proteomics and
RT-PCR.
Similarly, ﬁxing the brain whole or as an intact
hemisphereisnotanoptimaluseoftheresource asthis
results in extreme ﬁxation gradients across the tissue,
with brain surfaces becoming over-ﬁxed while interior
regions are under-ﬁxed. These ﬁxation gradients make
even semi-quantitative immunohistohchemical evalu-
ationverydifﬁcult,although aminorityofepitopesare
tolerant to this. While perfusion-ﬁxation of the
postmortem brain through the circle of Willis (the
entire cerebrum or one hemisphere can be ﬁxed this
way) is the optimal ﬁxation method, this is time-
consuming and we have found that ﬁxation of 1 cm-
thick slices for 24–48 h at 4C is a reasonable
compromise (Beach et al. 1987).
To aid in the production of uniformly-thick fresh
brain slices for freezing and ﬁxation, we have
developed a brain slicing apparatus (jig) that holds
the brain together while being sliced. With the
assistance of a retired engineer living in Sun City
and a contracted fabrication company (AvTek, Inc,
Phoenix, AZ), we have enabled its semi-automated
duplication by entering the 3-dimensional plans for
the apparatus onto a computer. We have made this
available and known to other brain banks.
Fixation is continued for 2 days at 4C. Following
ﬁxation, diagnostic tissue blocks are taken from 28
brain regions (Table 2) for embedding in parafﬁn
wax; additionally, 8 large (about 3 9 4 cm) tissue
blocks, representing all cerebral lobes as well as
cerebellum and brainstem (Table 2), following cryo-
protection in 2% DMSO/20% glycerol, are sectioned
at 40 lm on a sledge-type freezing microtome. These
thick sections are superior to standard autopsy brain
parafﬁn blocks for both silver stains and immunohis-
tochemistry, due to their relatively light ﬁxation
(Beach et al. 1987; Leong and Gilham 1989), thick-
ness (allowing full visualization of 3-D structure),
structural integrity (allowing processing as free-ﬂoat-
ing sections, which improves antibody access and
washing) and lack of exposure to hot parafﬁn wax
(Pollard et al. 1987). These large-format sections also
offer the opportunity for grading of periventricular
white matter rarefaction (Fig. 2a) and an extensive
survey for microscopic infarctions. Pre-cut free-ﬂoat-
ing 40 lm sections, as well as unsectioned ﬁxed wet
brain blocks, are stored at -20C in a solution
composed of 30% ethylene glycol, 30% glycerol in
0.1 M phosphate buffer. Sections prepared in this
manner have been used successfully for immunohis-
tochemical studies after two decades of storage.
Diagnostic stains
Sections from parafﬁn blocks are cut at 6 lm and
stained with hematoxylin and eosin (H & E). Parafﬁn
sections from the anterior cingulate gyrus, amygdala,
entorhinal cortex, middle frontal gyrus, middle tem-
poral gyrus, inferior parietal lobule, anterior medulla
and olfactory bulb are stained immunohistochemi-
cally for a-synuclein to identify Lewy bodies and
Lewy-related neurites. Sections from the large frozen
blocks are stained with Campbell-Switzer, Gallyas
(Braak and Braak 1991) and Thioﬂavine S methods
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additional sections are stained with H & E to detect
and grade periventricular cerebral white matter
rarefaction (leukoaraiosis) and microinfarctions
(Fig. 2). At a section thickness of 40 lm, we have
found that H & E is superior to Luxol Fast Blue for
detection of white matter changes. Additional immu-
nohistochemical procedures are used as needed,
including those for phosphorylated tau protein to
detect atypical tauopathies, ubiquitin to detect intran-
euronal inclusions of frontotemporolobar dementia
with ubuiquinated inclusions, and aB-crystallin and/
or phosphorylated neuroﬁlament to detect swollen
neurons in corticobasal degeneration. For all stains
except H & E, positive control sections are always
included in order to standardize staining results from
batch to batch.
Diagnosis of neurodegenerative disorders
Diagnostic criteria have been amply discussed in the
literature and will not be reviewed here. For a
summary of the current general approach, the reader
is referred to a recently-published algorithm (Dickson
2005). Published clinicopathologic consensus criteria
are used for most conditions, incorporating clinical
determinations of cognitive status and the presence or
absence of other neurologic signs as well as pertinent
medical history. The diagnoses of cases coming to
autopsy in the Brain Donation Program since 1997
are given in Table 3. The frequency of different
conditions reﬂects recruiting priorities, which have
been focused on normal elderly controls, Alzheimer’s
disease and Parkinson’s disease. Noteworthy, how-
ever, are the relatively high frequencies of non-
Alzheimer’s dementias, particularly dementia with
Lewy bodies, progressive supranuclear palsy and
hippocampal sclerosis, all of which have often come
to autopsy as clinically-diagnosed Alzheimer’s dis-
ease. Also notable is the frequent co-existence of
more than one major neuropathological condition in
the same subject.
Table 2 Brain regions sampled for diagnostic histopathology
and inventory
Brain region Parafﬁn 6 lm
sections
Frozen 40 lm
sections
Superior frontal gyrus No Yes
Middle frontal gyrus Yes Yes
Precentral gyrus Yes No
Postcentral gyrus Yes No
Superior parietal lobule No Yes
Inferior parietal lobule Yes No
Anterior cingulate gyrus Yes Yes
Superior temporal gyrus No Yes
Middle temporal gyrus Yes Yes
Inferior temporal gyrus No Yes
Fusiform gyrus Yes Yes
Parahippocampal gyrus at
amygdala
Yes Yes
Parahippocampal gyrus at
head hip.
No Yes
Parahippocampal gyrus at
lat. genic.
Yes Yes
Hippocampus at head No Yes
Hippocampus at body Yes Yes
Occipital cortex: primary Yes Yes
Occipital cortex:
association
Yes Yes
Cerebral white matter: all
lobes
No Yes
Caudate nucleus: head No Yes
Caudate nucleus: body Yes Yes
Putamen: head No Yes
Globus pallidus Yes Yes
Substantia innominata Yes Yes
Thalamus: anterior Yes Yes
Thalamus: midpoint Yes Yes
Hypothalamus Yes Yes
Mammillary body Yes No
Subthalamic nucleus Yes Yes
Substantia nigra No Yes
Midbrain tegmentum No Yes
Pons: anterior Yes No
Pons: midpoint Yes Yes
Cerebellum: vermis Yes No
Cerebellum: dentate
nucleus
Yes Yes
Cerebellum: hemispheric
cortex
Yes Yes
Medulla: anterior Yes No
Medulla: posterior Yes No
Table 2 continued
Brain region Parafﬁn 6 lm
sections
Frozen 40 lm
sections
Olfactory bulb and tract Yes No
Spinal cord: cervical Yes No
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Since the discovery of the increased risk for
Alzheimer’s disease that is attributable to the
presence of the e4 allele of the apolipoprotein E
gene (apoE), numerous investigations have shown
that some clinicopathologic characteristics of the
disease are different in e4 carriers vs non-carriers.
Therefore it is important, when designing studies
involving Alzheimer’s disease tissue, to analyze the
data taking e4 genotype into account. Since January
1999 it has been our objective to genotype every
case coming to autopsy, with 730 cases done to
date. The testing has been performed using a
standard technique (Hixson and Vernier 1990), with
DNA isolated from our lightly-ﬁxed cerebellar
samples as described previously (Beach et al.
2003). We have found this method more convenient
than using fresh-frozen tissue although the method
is unsuitable for brain tissue ﬁxed in formalin for
the standard interval of 10 days to 2 weeks; in these
cases we use fresh-frozen cerebellum. We periodi-
cally perform quality control studies, having a series
of our apoE-genotyped cases repeated by another
laboratory. Isolated DNA remaining after apoE
genotyping is stored for future studies. Screening
for other mutations associated with neurodegenera-
tive conditions (e.g. triplet repeat expansion dis-
eases, spinocerebellar degenerations, progranulin
mutations) is performed by outside collaborating
laboratories when family history, clinical features
and/or histopathology are suggestive of a particular
condition.
Assessment of agonal state
Agonal status impacts tissue quality, as fever, ische-
mia-hypoxia and acidosis are deleterious to many
Fig. 2 Photomicrographs
of 40 lm frozen sections
stained according to our
standard protocols. (a)
Frontal lobe stained with H
& E, showing
periventricular white matter
rarefaction; (b)
hippocampus stained with
the Campbell-Switzer silver
method, showing senile
plaques and neuroﬁbrillary
tangles; (c) neuroﬁbrillary
tangles stained with the
Gallyas silver method; (d)
neuron in the dentate gyrus
granular cell layer stained
immunohistochemically for
phosphorylated tau protein
with the AT8 antibody; (e)
tufted astrocyte stained with
the Gallyas method; (f)
thorned astrocyte stained
with the Gallyas method;
(g) oligodendroglial coiled
body stained with the
Gallyas method
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123molecules of interest (Harrison et al. 1995; Hynd
et al. 2003; Johnston et al. 1997; Li et al. 2004;
Morrison-Bogorad et al. 1995; Perry et al. 1982;
Spokes 1979). However, agonal status is difﬁcult to
determine in elderly subjects, who usually die in a
nursing home without close medical supervision. The
pH of CSF and/or brain tissue has been used as a
surrogate marker for agonal status (Ravid et al.
1992). Some studies have reported that when the
agonal state, as inferred from clinical data, is
expected to have been detrimental, for example in
cases of prolonged mechanical ventilation, the pH is
low (e.g. pH 5.5–6.0), while in cases of sudden death
it is higher, closer to normal (e.g. 7.0–7.4) (Hardy
et al. 1985; Perry et al. 1982). Some enzyme activ-
ities and measures of RNA integrity have correlated
with postmortem pH, but not in all studies or for all
subtypes of these molecules (Kingsbury et al. 1995;
Li et al. 2004; Spokes 1979; Stan et al. 2006; Yates
et al. 1990). Two recent comprehensive studies may
have resolved the variability in prior reports, as it was
found that only pH values under about 6.5–6.8 were
associated with decreased RNA integrity (Li et al.
2004; Stan et al. 2006).
We conducted our own study of postmortem CSF
pH as a marker of tissue viability by correlation with
viable cell yield in postmortem glial cultures,
reasoning that physiologically damaging agonal con-
ditions would result in a decreased yield of viable
cells taken from that tissue.
The viable cell yield from 46 consecutive cell
culture cases was compared with their respective CSF
pH and PMI. Brain tissue for culture was obtained
from the cerebral white matter of the centrum
ovale. Viable cell yield ranged from 0.74 to
6.47 9 10
6 cells/g brain tissue. The CSF pH ranged
from 6.36 to 7.19 (mean 6.73). Post-mortem interval
ranged from 1.5 to 4.5 h. Multiple linear regression
analysis indicated that CSF pH was not a signiﬁcant
independent predictor of viable cell yield (R = 0.12,
P = 0.45). Postmortem interval, however, was
signiﬁcantly related (inversely) to viable cell yield,
(R = 0.28, P = 0.06). A surprising result was that
PMI was signiﬁcantly correlated (inversely) with CSF
pH (R = 0.37, P = 0.01), in agreement with one
other group (Catts et al. 2005) but in disagreement
with several other reports (Karkela 1993; Kingsbury
et al. 1995; Stan et al. 2006). The difference between
our results and those of other groups may be due to our
uniformly short PMI, as other studies have included
many cases with much longer PMIs. It is likely that
brain cells surviving after death are generating lactic
acid via anaerobic metabolism. As the PMI increases,
fewer and fewer cells are alive and eventually all cells
will be dead. At some point in this process, it is
probable that pH would eventually stabilize. There-
fore studies that have primarily involved cases with
longer PMI’s may not ﬁnd any relationship between
PMI and pH. We have not performed both RNA
integrity assessments and CSF pH measurement on
enough cases to allow a meaningful correlation of
these factors as yet.
Our results suggest, therefore, that CSF progres-
sively acidiﬁes with increasing postmortem interval
but that it is not a useful predictor of tissue
viability, at least for cases with PMIs in the 1–5 h
range. We have decided that direct assessment of
tissue preservation is preferable to indirect markers
such as CSF pH or agonal medical history collec-
tion. As RNA is one of the most important
molecular species for research uses, we have been
using RNA quality, assessed qualitatively in RNA
gels as described above, as a general indicator of
tissue quality.
Table 3 Neuropathological diagnoses, 1997–2007
Neuropathological diagnosis N %
Normal
a 119 21
Alzheimer’s disease 316 56
Dementia with Lewy bodies 99 18
Parkinson’s disease 78 14
Vascular dementia 43 8
Progressive supranuclear palsy 41 7
Hippocampal sclerosis 35 6
Dementia lacking distinctive histology 9 2
Multiple system atrophy 5 0.9
Motor neuron disease with dementia 3 0.5
Corticobasal degeneration 2 0.4
Pick’s disease 2 0.4
Huntington’s disease 2 0.4
As more than one condition was often present in a single
subject, the sum of the percentages exceeds 100
a No major clinical neurological diagnosis & age-consistent
neuropathology only
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important brain regions
One of the limitations of brain banking for neurode-
generative disease research is that some of the most
important brain regions are very small and just one or
two studies may entirely deplete the tisssue. Exam-
ples of these small yet vital regions are the entorhinal
cortex, hippocampus, amygdala and substantia nigra.
To overcome this limitation and distribute tissue from
these regions to greater numbers of researchers, we
have been sectioning these brain areas on a cryostat
and providing researchers with samples of 5–10
cryostat sections per case. This has been found
sufﬁcient to allow 5–6 Western blot analyses for
proteins of interest and numerous RNA analyses for
studies of gene expression. Conservatively, we esti-
mate that this will increase utilization by 10-fold or
greater.
Serial sectioning of substantia nigra for unbiased
stereologic morphometry
Accurate counting of neurons within deﬁned brain
regions requires the methods of unbiased stereology
(Gundersen et al. 1988; West 1999) and a complete
sampling of the brain region of interest. For cases
with clinical parkinsonism, as well as many control
cases, we have serially sectioned the substantia nigra
to allow unbiased estimates of neuron numbers. The
entire left side of the substantia nigra is serially
sectioned at 40 lm on a sliding freezing microtome,
with all sections collected and stored appropriately.
To date, 146 cases have been serially sectioned in this
manner. The method is very time-consuming, how-
ever, and as an alternative, researchers should
consider biochemical analysis of dopaminergic mark-
ers in the striatum as perhaps a more quantitative and
sensitive indicator of the integrity of the nigrostriatal
dopaminergic system (Beach et al. 2004).
Brain and Body Donation Program with full
autopsies
The SHRI Brain Donation Program expanded its
operations in September 2005 by offering whole-
body donation to all enrolled subjects and to newly-
recruited subjects. Since that time, approximately 600
former brain-only donors have consented to whole-
body donation and we have performed more than 50
such autopsies, extending our rapid postmortem
banking procedures to all major bodily organs and
tissues. Although this expansion has been done in the
interest of pursuing research in diseases of other
organ systems, it has been increasingly recognized
that concurrent disease in other organ systems may
contribute to the clinical expression of neurodegen-
erative disease. Banking tissue from throughout the
body has also helped diversify our funding sources,
allowing for greater ﬁnancial stability.
Study of freeze-thaw effects and CSF pH on tissue
RNA integrity
We have long suspected, on the basis of our tissue
banking experience, that most of the molecular
degradation that occurs in banked tissue is due to
repeated freeze-thaw cycles, which occur due to
improper handling during dissection for tissue
retrieval or due to freezer malfunctions. Our freezers
are currently protected by temperature-sensitive
alarms that automatically telephone maintenance
and tissue banking personnel when the temperature
reaches a certain level. More protection is preferable,
with CO2 tanks for backup cooling the optimum (but
expensive) approach. We plan to systematically
investigate the effects of thawing and refreezing on
RNA integrity, by deliberately thawing and freezing
small samples of brain tissue over varying time
intervals and temperatures.
Biological materials allocation procedure
Requests for biological materials are granted by a
committee of SHRI scientists on the basis of avail-
ability and scientiﬁc merit. Investigators must ﬁrst
establish appropriate scientiﬁc credentials by provid-
ing a recent biosketch or curriculum vita. The request
is generally granted if it is small or does not seriously
deplete a particular resource but receives greater
scrutiny if it is for a small, critical area like
hippocampus or if it is a large request requiring
several days to put together. A base charge of $2000
is required to ﬁll a typical small request, in order
to partially recover the costs of the neuropatholo-
gist’s and coordinator’s time assisting with study
design, case selection, database searches, retrieval
and/or dissection, packaging, shipping and continuing
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tionately larger cost recovery fees. Requests from
for-proﬁt companies are negotiated on a contract-by-
contract basis, with generally larger fees assessed.
The general principle applied to all tissue transactions
at SHRI is that the user should help defray the
expenses of running the program. As academic users
generally do not have large budgets, their ability to
pay is limited. Rather than deny these users access to
the resource, we generally grant their requests even
though their payments are less than our costs. As for-
proﬁt organizations are often able to reimburse us the
full cost of the tissue, negotiations generally aim to
obtain this. We have calculated that the cost of
following one subject with annual clinical assess-
ments until death, and then performing the autopsy,
the neuropathological examination, tissue storage,
database upkeep and responding to tissue requests, is
at least $20,000 per subject, based on the annual
operating expenses of the program (clinical and
postmortem costs) divided by the number of autop-
sies per year. The fees charged to users generally
never come close to meeting the operating costs. In a
typical year, user fees recoup less than 10% of our
costs. Therefore we consider it ethically sound to
pursue higher payments from organizations that have
greater resources, and these are generally for-proﬁt
organizations. In practice, the majority of the pro-
gram’s funding comes from competitive grants,
including subcontracts on investigator-initiated
research grants and dedicated core grants (SHRI has
the Neuropathology Core for the National Institute
on Aging’s Arizona Alzheimer’s Disease Core
Center and the Neuropathology Core for the state
of Arizona-funded Arizona Parkinson’s Disease
Center).
Distribution of biological materials to researchers
Over a recent 4-year-period (01/01/2001–08/16/
2005), 270 separate distributions, each representing
a separate tissue retrieval and shipment of a set of
requested samples, were made. Of these, 174 distri-
butions were to 20 separate Arizona ADCC-afﬁliated
researchers while 95 distributions were to 33 different
researchers located outside of the Arizona ADCC.
Over this same time period, biological materials
supplied by the SHRI Brain Donation Program
supported more than 49 grants to 26 researchers
and a total of 71 publications. Of the 53 researchers
supplied, 50 worked for ‘‘not-for-proﬁt’’ organiza-
tions while 3 were from ‘‘for-proﬁt’’ organizations.
Protection of neuropathology core workers
and tissue users
Health risks to individuals exposed to human tissue
are minimized by the use of a number of precaution-
ary measures. The process begins with screening of
medical records at the time of enrollment and
repeated screens with each clinical visit and at the
time of death. Those individuals with a medical
history of a serious infectious pathogen are excluded
from enrollment or autopsy. This includes individuals
with active or carrier status for hepatitis B, hepatitis
C, HIV, syphilis, tuberculosis, Creutzfeldt-Jakob
disease (CJD) and acute or chronic active CNS
infections of any type. As SHRI is a private research
organization, not a diagnostic autopsy service, it is
our option to refuse to perform an autopsy. In the 10-
years since this telephone protocol was developed,
only four subjects have been rejected for the presence
of a hazardous infectious disease at the time of death,
reﬂecting the low rate of these infectious diseases in
our study population. Three of these rejections were
for high risk of CJD, and one of the three was later
conﬁrmed as CJD by the National Prion Disease
Surveillance Laboratory at Case Reserve University
in Cleveland. The fourth rejection was for sepsis with
methicillin-resistant Staphylococcus aureus.
Staff involved in brain removal and tissue pro-
cessing are encouraged to have hepatitis A and B
vaccination; during procedures involving exposure to
fresh or frozen human tissue, staff wear protective
clothing including hoods or caps, eye protection,
masks, gowns, gloves and boots. Postmortem blood
serum from each autopsied patient is sent for
diagnostic serology for the detection of hepatitis B
and C, syphilis and HIV. If any of these are indicative
of the presence of these pathogens, all fresh or frozen
tissue is discarded. If potentially infectious contam-
ination of an individual occurs, such as splashing of
fresh tissue ﬂuids into the eyes or into a wound, the
individual receives appropriate ﬁrst aid measures at
the scene and then is taken to a nearby Emergency
Room. All Institute staff receive, upon ﬁrst hiring, a
full day of training in laboratory safety, including
biohazard safety precautions.
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It is anticipated that continual technological advances
will allow ever more reﬁned investigations into the
molecular basis of disease. There will thus continue to
be a need for brain banks, and the importance of the
tissueis likely to increase as the methods become more
powerful. Additionally, as the number of subjects with
banked tissue and neuropathological diagnoses
increases, population-level investigations using epide-
miological methods will be possible. Such ‘‘autopsy-
veriﬁed epidemiology’’ has the potential to add
precision to the knowledge base that has previously
been based on clinical diagnoses, with their inherently
higherrateofdiagnosticmisclassiﬁcation.AtSHRI,our
primary ﬁeld of study will continue to be normal aging
and age-related disease. We will strive to increasingly
relate molecular-level ﬁndings not only to physiology,
but also to health care, behavior, sociology and
economics. Through this multifaceted approach, we
hope to help reduce the negative aspects of aging.
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